Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Simmons

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Opinion in Pharmacology|June 16, 2005
Anti-adhesion therapiesDavid L Simmons
Drug Discovery Today|April 4, 2006
What makes a good anti-inflammatory drug target?David L Simmons
Current Opinion in Pharmacology|March 26, 2013
Targeting kinases: a new approach to treating inflammatory rheumatic diseasesDavid L Simmons
Arthritis and Rheumatism|September 18, 2003
Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissuePaul F Bradfield, Nicole Amft, Elizabeth Vernon-Wilson, et al.
Arthritis and Rheumatism|May 30, 2009
Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathwaysAndrew Filer, Magdalena Bik, Greg N Parsonage, et al.
The Journal of Experimental Medicine|September 21, 2005
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitisSuzana Marusic, Michael W Leach, Jeffrey W Pelker, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Opinion in Pharmacology|June 16, 2005
Anti-adhesion therapiesDavid L Simmons
Drug Discovery Today|April 4, 2006
What makes a good anti-inflammatory drug target?David L Simmons
Current Opinion in Pharmacology|March 26, 2013
Targeting kinases: a new approach to treating inflammatory rheumatic diseasesDavid L Simmons
Arthritis and Rheumatism|September 18, 2003
Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissuePaul F Bradfield, Nicole Amft, Elizabeth Vernon-Wilson, et al.
Arthritis and Rheumatism|May 30, 2009
Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathwaysAndrew Filer, Magdalena Bik, Greg N Parsonage, et al.
The Journal of Experimental Medicine|September 21, 2005
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitisSuzana Marusic, Michael W Leach, Jeffrey W Pelker, et al.
Pageof 1